Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

Next Previous
X
Search
Trial Profile

Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SB-121 (Primary)
  • Indications Autistic disorder
  • Focus Adverse reactions; First in man
  • Sponsors Scioto Biosciences

    • Most Recent Events

    • 03 Apr 2023 According to a Scioto Biosciences media release, results from this study was published in the journal Scientific Reports.
    • 03 Apr 2023 Results published in the Scioto Biosciences Media Release
    • 26 May 2022 Results presented in a Scioto Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top